NCT00951457View on ClinicalTrials.gov

Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

August 6, 2012

Study Completion Date

August 6, 2012

Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
DRUG

Bendamustine

DRUG

Alemtuzumab

Trial Locations (7)

A-6020

Medizinische Universitaet Innsbruck, Abtlg. f. Haematologie und Onkologie, Innsbruck

A-6806

Landeskrankenhaus Feldkirch, Feldkirch

A-8700

A.ö. Landeskrankenhaus Leoben, Leoben

A-4010

Krankenhaus der Elisabethinen Linz, Linz

A-4020

Krankenhaus der Stadt Linz, Linz

A-5020

Universitaetsklinik f. Innere Medizin III, Salzburg

A-4600

Klinikum Wels-Grieskirchen GmbH, Wels

Sponsors

Collaborators (1)

Mundipharma Pte Ltd.
All Listed Sponsors
collaborator

Mundipharma Pte Ltd.

INDUSTRY

lead

Arbeitsgemeinschaft medikamentoese Tumortherapie

OTHER

NCT00951457 - Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) | Biotech Hunter | Biotech Hunter